TOBIN JAMES R sold $385K of TMDX

TOBIN JAMES R sold 4,059 shares of TransMedics Group, Inc. (TMDX) at an average of $94.97 ($93.96–$94.98, $0.39M total) across 2 trades on 2026-11-09.

Original reporting
SEC EDGAR · TOBIN JAMES R
Published Nov 12, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMDX
Bearish
medium confidence
Mentioned
$TMDX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMDXBearishLow
01

Why it matters

Director's sale may be interpreted as a slight negative signal, but size is modest.

02

Market read

Small insider sale with limited market impact; primarily of interest to short‑term traders monitoring insider activity.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: after market filing on 2026‑11‑12

Background

SEC Form 4 filing discloses insider transactions required by regulation.

Company-level read

Ticker impact

$TMDXBearishMedium confidence
Context

Director Tobin James R sold 4,059 shares of TransMedics Group for $385K via open‑market transactions on 2026‑11‑09.

Expected impact

potential modest pressure as the market prices in the director's share disposal

Evidence & confidence

A director selling a few thousand shares at near $95 each is a small but material signal; investors may view it as a negative cue.

Market effects

Limited impact on the broader medical device sector; insider sales are company‑specific.

No significant regional effect; confined to TransMedics shareholders.

Minimal global relevance; isolated insider transaction.

Counterpoint

The sale could be routine liquidity need and not indicative of future performance.

Key entities

  • TransMedics Group, Inc.

    US‑listed medical device company (ticker TMDX).

  • Tobin James R

    Director of TransMedics Group.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

TransMedics revenue up 41% to USD 203M in Q3 2026

TransMedics reported Q3 2026 revenue of $203M, up 41% YoY, driven by increased organ transplant volumes and logistics services. Gross margin was 58.5%, with operating income of $28.1M. The company cited growth catalysts like ENHANCE Heart Part B and DENOVO Lung, and plans for European expansion. Net income fell to $17.1M, or $0.46 per share, from $24.3M, or $0.66 per share, a year earlier.

$TMDXMed

TransMedics Group Q3 Earnings Call Highlights

TransMedics Group reported Q3 product gross margin at 79.2% and service gross margin at 32.2%. Adjusted net income was $18.9M, or $0.51 per share, with $493M in cash. The company completed ENHANCE Heart Part A enrollment and plans submissions in 2027. It also targets European expansion and kidney platform trials in 2027, maintaining its full-year adjusted operating margin outlook of 12.5% to 14%.